■在中国和世界其他地区,针灸已被用于治疗神经和神经精神症状。这些症状,比如疲劳,头痛,认知障碍,焦虑,抑郁症,失眠,在经历长时间COVID的人中很常见。
■本研究旨在探讨针灸治疗长型COVID患者神经和神经精神症状的可行性。
■从成立到2023年6月23日,在四个英文和四个中文数据库中进行了系统搜索。由两对独立审稿人进行文献选择和数据提取。
■探索针刺对疲劳影响的随机对照试验(RCT),抑郁症,焦虑,认知异常,头痛,失眠也包括在内。
■探索针刺对疲劳影响的随机对照试验,抑郁症,焦虑,认知异常,头痛,失眠也包括在内。使用R软件进行荟萃分析。使用I2测量异质性。进行亚组分析,重点是治疗持续时间和针灸方式。系统审查方案已在PROSPERO上注册(注册号:CRD42022354940)。
■广泛采用的临床结果量表包括用于评估疲劳的疲劳量表,汉密尔顿抑郁量表用于评估抑郁,评估认知障碍的简易精神状态检查,头痛严重程度的视觉模拟量表,和匹兹堡睡眠质量指数来衡量失眠。
■共110项随机对照试验纳入系统评价和荟萃分析。总的来说,发现针灸可以改善疲劳量表的评分(与用药:均差(MD):-2.27,P<0.01;vs.假针刺:MD:-3.36,P<0.01),汉密尔顿抑郁量表(与用药:MD:-1.62,95%,P<0.01;vs.假针刺:MD:-9.47,P<0.01),迷你精神状态检查(vs.用药:MD:1.15,P<0.01;vs.假针刺:MD:1.20,P<0.01),视觉模拟量表(与用药:MD:-1.05,P<0.01;vs.候补名单:MD:-0.48,P=0.04),和匹兹堡睡眠质量指数(与用药:MD:-2.33,P<0.01;vs.假针刺:MD:-4.19,P<0.01)。
■这项系统评价表明,针灸是治疗神经和神经精神症状的潜在有益方法,用临床量表评估,它可能适用于长期COVID患者。需要进一步的精心设计的临床研究,专门针对长型COVID患者,以验证针灸在缓解长型COVID症状中的作用。
■PROSPERO,标识符[CRD42022354940]。
UNASSIGNED: Acupuncture has been used to treat neurological and neuropsychiatric symptoms in China and other parts of the world. These symptoms, such as fatigue, headache, cognitive impairment, anxiety, depression, and insomnia, are common in people experiencing long COVID.
UNASSIGNED: This study aims to explore the feasibility of acupuncture in the treatment of neurological and neuropsychiatric symptoms in long COVID patients.
UNASSIGNED: A systematic search was conducted in four English and four Chinese databases from inception to 23 June 2023. Literature selection and data extraction were conducted by two pairs of independent reviewers.
UNASSIGNED: Randomized controlled trials (RCTs) that explored the effect of acupuncture on fatigue, depression, anxiety, cognitive abnormalities, headache, and insomnia were included.
UNASSIGNED: RCTs that explored the effect of acupuncture on fatigue, depression, anxiety, cognitive abnormalities, headache, and insomnia were included. A meta-analysis was performed using R software. Heterogeneity was measured using I2. Subgroup analyses were performed focusing on the duration of treatment and acupuncture modalities. The systematic
review protocol was registered on PROSPERO (registration number: CRD42022354940).
UNASSIGNED: Widely adopted clinical outcome scales included the Fatigue Scale for assessing fatigue, the Hamilton Depression Rating Scale for evaluating depression, the Mini-Mental State Examination for assessing cognitive impairment, the Visual Analog Scale for headache severity, and the Pittsburgh Sleep Quality Index for measuring insomnia.
UNASSIGNED: A total of 110 RCTs were included in the systematic
review and meta-analysis. Overall, acupuncture was found to improve the scores of the Fatigue Scale (vs. medication: mean differences (MD): -2.27, P < 0.01; vs. sham acupuncture: MD: -3.36, P < 0.01), the Hamilton Depression Rating Scale (vs. medication: MD: -1.62, 95%, P < 0.01; vs. sham acupuncture: MD: -9.47, P < 0.01), the Mini-Mental State Examination (vs. medication: MD: 1.15, P < 0.01; vs. sham acupuncture: MD: 1.20, P < 0.01), the Visual Analog Scale (vs. medication: MD: -1.05, P < 0.01; vs. waitlist: MD: -0.48, P=0.04), and the Pittsburgh Sleep Quality Index (vs. medication: MD: -2.33, P < 0.01; vs. sham acupuncture: MD: -4.19, P < 0.01).
UNASSIGNED: This systematic
review suggested acupuncture as a potentially beneficial approach for the treatment of neurological and neuropsychiatric symptoms, as assessed using clinical scales, and it may have applicability in long COVID patients. Further well-designed clinical studies specifically targeting long COVID patients are needed to validate the role of acupuncture in alleviating long COVID symptoms.
UNASSIGNED: PROSPERO, identifier [CRD42022354940].